Aclarion Inc experiences significant drop amid market fluctuations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 Dec 25
Source: Coinmarketcap
Aclarion Inc's stock price fell by 11.24%, crossing below its 5-day SMA, reflecting a challenging trading environment.
This decline is attributed to broad market weakness, with the Nasdaq-100 down 0.58% while the S&P 500 showed slight gains. The contrasting performance indicates sector rotation, as investors may be reallocating their portfolios in response to market conditions.
The implications of this movement suggest that Aclarion Inc may face continued pressure unless there are positive developments or shifts in market sentiment that could restore investor confidence.
Analyst Views on ACON
Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.640
Low
23.00
Averages
23.00
High
23.00
Current: 3.640
Low
23.00
Averages
23.00
High
23.00

No data
About ACON
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





